Overview

Crossover Bioequivalence Study of Cevimeline 30 mg Capsules Under Fasted Conditions

Status:
Completed
Trial end date:
2009-02-01
Target enrollment:
Participant gender:
Summary
The objective of this study was to prove the bioequivalence of Roxane Laboratories' Cevimeline 30 mg under fasted conditions
Phase:
Early Phase 1
Details
Lead Sponsor:
Roxane Laboratories
Treatments:
Cevimeline